A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de novo Kidney Transplantation

Yang, Harold C.; Vincenti, Flavio; Klintmalm, G; Steinberg, Steven; Wang, L.; Zhang, W.; Conkle, Angela; Shrivastava, A.; Blahunka, Paul; First, Roy; Holman, John

doi:10.1097/00007890-201211271-00147

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, ASKP1240 is another promising anti-CD40 monoclonal antibody that has been shown to be well tolerated without cytokine release syndrome or thromboembolic events in a phase I study in healthy subjects [135]. A separate clinical study in patients following kidney transplantation has demonstrated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASKP1240 [136].…”

Section: Cd40 and Cd40l Blockade In Kidney Transplantationmentioning

confidence: 99%

CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease

Zhang

Breidenbach

Russell

et al. 2020

JCM

View full text Add to dashboard Cite

The cluster of differentiation 40 (CD40) is activated by the CD40 ligand (CD40L) in a variety of diverse cells types and regulates important processes associated with kidney disease. The CD40/CD40L signaling cascade has been comprehensively studied for its roles in immune functions, whereas the signaling axis involved in local kidney injury has only drawn attention in recent years. Clinical studies have revealed that circulating levels of soluble CD40L (sCD40L) are associated with renal function in the setting of kidney disease. Levels of the circulating CD40 receptor (sCD40), sCD40L, and local CD40 expression are tightly related to renal injury in different types of kidney disease. Additionally, various kidney cell types have been identified as non-professional antigen-presenting cells (APCs) that express CD40 on the cell membrane, which contributes to the interactions between immune cells and local kidney cells during the development of kidney injury. Although the potential for adverse CD40 signaling in kidney cells has been reported in several studies, a summary of those studies focusing on the role of CD40 signaling in the development of kidney disease is lacking. In this review, we describe the outcomes of recent studies and summarize the potential therapeutic methods for kidney disease which target CD40.

show abstract

Section: Cd40 and Cd40l Blockade In Kidney Transplantationmentioning

confidence: 99%

CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease

Zhang

Breidenbach

Russell

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…There was no difference in the incidence of infection based on dose, but B cell CD40 receptor occupancy trended to be prolonged as the dose increased (71). Phase II trials are currently in development (36).…”

Section: Askp1240mentioning

confidence: 99%

“…A clinical trial assessing the bioavailability of ASKP1240 in healthy subjects after intravenous and subcutaneous administration was recently completed in September 2012 and demonstrated that ASKP1240 was well tolerated in the range of 50 to 500 mg, with no evidence of cytokine release syndrome or thromboembolic events. There was no difference in the incidence of infection based on dose, but B cell CD40 receptor occupancy trended to be prolonged as the dose increased ( 71 ). Phase II trials are currently in development ( 36 ).…”

Section: Askp1240mentioning

confidence: 99%

New immunosuppressive agents in pediatric transplantation

Nguyen¹,

Shapiro²

2014

Clinics

View full text Add to dashboard Cite

Immunosuppressive therapy in pediatrics continues to evolve. Over the past decade, newer immunosuppressive agents have been introduced into adult and pediatric transplant patients with the goal of improving patient and allograft survival. Unfortunately, large-scale randomized clinical trials are not commonly performed in children. The purpose of this review is to discuss the newer immunosuppressive agents available for induction therapy, maintenance immunosuppression, and the treatment of rejection.

show abstract

A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de novo Kidney Transplantation

Cited by 2 publications

References 0 publications

CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease

CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease

New immunosuppressive agents in pediatric transplantation

Contact Info

Product

Resources

About